Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, January 10, 2023
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
[ Tue, Jan 10th 2023
] - WOPRAI
Edward Tenthoff Maintained (STRO) at Buy with Increased Target to $18 on, Jan 10th, 2023
Edward Tenthoff of Piper Sandler, Maintained "Sutro Biopharma, Inc." (STRO) at Buy with Increased Target from $16 to $18 on, Jan 10th, 2023.
Edward has made no other calls on STRO in the last 4 months.
There is 1 other peer that has a rating on STRO. Out of the 1 peers that are also analyzing STRO, 0 agree with Edward's Rating of Hold.
This is the rating of the analyst that currently disagrees with Edward
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $20 on, Wednesday, November 9th, 2022
